Roche Says FDA's Evaluation Of This Columvi Combination For R/R Dlbcl Is Ongoing And A Decision On Approval Is Expected By 20 July 2025

RefinitivCzytanie zajmuje mniej niż 1 minutę

Roche Holding AG RO:

ROCHE PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING ON COLUMVI COMBINATION FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
ROCHE HOLDING AG - FDA'S EVALUATION OF THIS COLUMVI COMBINATION FOR R/R DLBCL IS ONGOING AND A DECISION ON APPROVAL IS EXPECTED BY 20 JULY 2025

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Zaloguj się lub utwórz zawsze darmowe konto, aby przeczytać te wiadomości